Pituitary adenomas comprise 10% to 15% of all intracranial tumors in
adults. In addition, 10% of normal adults have asymptomatic abnormalities
on MRI that are consistent with a pituitary adenoma, and perhaps 20% or
more are found to have an asymptomatic adenoma on autopsy.[1,2] Patients
requiring intervention have a characteristic constellation of signs and
symptoms that are easily recognized by the astute primary care physician.
Furthermore, these signs and symptoms are critical gauges for the specialist
neurosurgeon, endocrinologist, and radiation oncologist in recommending
Once a pituitary adenoma is suspected, diagnostic evaluation with hormonal
and neuroradiologic studies is indicated. These studies, along with patient
status, preference, and symptoms, guide decisions about medical, surgical,
or radiotherapeutic management. Each of these therapies has distinct and
characteristic profiles of response and toxicity that influence the recommended
treatment plan. In nearly all cases of benign tumors, the possibility of
cure exists. This probability of cure should be maximized at the time of
primary diagnosis and treatment because multiple recurrences of benign
tumors may lead to increased morbidity with further treatment and perhaps,
in some cases, to increased mortality from the disease.
Patients with pituitary adenomas usually have either neurologic or hormonal
manifestations of their disease. The most commonly reported neurologic
symptoms are headache and visual disturbances. Other cranial nerve palsies
and mental deterioration are reported less often but may occur more frequently
with giant adenomas.
Endocrinopathies may cause a host of patient complaints, ranging from
the polyuria and polydipsia of diabetes insipidus (rare) to menometrorrhagia
attributable to abnormal prolactin, luteinizing hormone, or follicle-stimulating
hormone levels. Decreased libido and general apathy may be related to luteinizing-hormone
deficiency or panhypopituitarism. Skin changes may occur and produce symptoms
indicative of imbalances in pituitary hormones, including thyroid and adrenal
hormones. Finally, the stigmata of Cushing's disease may lead the patient
to complain of a myriad of difficulties, ranging from irritability to a
change in body habitus, diabetes, hypertension, or easy bruising. Patients
with acromegaly also have characteristic stigmata, which family members
may slowly recognize as a change from their former appearance.
Although the development of these symptom complexes is usually insidious
from the patient's perspective, the clinicopathologic features of pituitary
adenomas often make them readily suspected at the time of diagnosis.
Clinicopathologic syndromes can be identified based on the patient's
signs and symptoms and physical findings, as well as the results of biochemical
evaluation. These syndromes may be divided into those of primarily neurologic
vs hormonal character.
Pituitary adenomas frequently extend beyond the sella proper. In general,
the path of tumor growth is upward, which pushes the optic chiasm superiorly.
Suprasellar extension may also cause headache and pressure on the pituitary
stalk, which may cause hormonal abnormalities independent of the tumor's
Presentations of classic bitemporal hemianopia represent the pure form
of this model of injury. More often, however, the patient may have a partial
hemianopia and blurred vision in the lateral fields. Rigorous pretherapy
ophthalmologic assessment is necessary to accurately gauge the outcome
of intervention and the severity of injury at presentation.
Headaches are a common neurologic complaint. These may be due to a direct
pressure effect of the tumor, an obstructive hydrocephalus effect (rare),
direct hormonal perturbation, or induction of secondary hypertension.
Other cranial nerve palsies may result from direct invasion of the cavernous
sinus or, less often, from erosion of the skull base and anterior clivus.
Deficits of the oculomotor, abducens, or trigeminal nerves occur most frequently.
More serious deficits than those described above are rare because these
tumors generally progress slowly and symptoms of cranial nerve deficits
related to vision usually attract medical attention in all but the most
stoic of patients. Thus, the majority of patients have one or more of the
neurologic clinicopathologic syndromes described above or have hormonal
difficulties that lead to diagnosis before gross neurologic dysfunction
Adrenocorticotrophic hormone (ACTH) overproduction leads to stigmata
of Cushing's disease. These may include diabetes, hypertension, infertility,
menstrual irregularity, proximal muscle weakness and atrophy, and skin
changes, including easy bruisability, striae, and hirsutism. Changes in
body habitus caused by excessive adrenal cortisol include characteristic
moon facies, truncal obesity, and humpback appearance, along with wasting
and weakness of the proximal extremities. However, the specific manifestations
seen in a given patient vary greatly and may sometimes be subtle. Furthermore,
the absence of radiographic findings of these macroadenomas often contributes
to difficulty in making a diagnosis. Therefore, the clinician must be vigilant
for these many signs of disease so as to order appropriate laboratory screening
tests. These tests will help locate the origin of hypercortisol production
so that appropriate therapy is delivered.
Approximately 5% to 10% of pituitary tumors cause elevated cortisol
levels, and an additional 5% are positive for ACTH on immunocytochemistry
Growth Hormone--Pituitary adenoma is the most common cause of
acromegaly. Overproduction of growth hormone is the third most common anomaly
seen in pituitary adenomas, with nonfunctioning adenomas and prolactinomas
occurring more frequently.
Excess production of growth hormone by a pituitary adenoma leads to
acromegaly in an adult or gigantism in a child. Stigmata of acromegaly
include coarsening of facial features, excess growth and thickening of
the distal phalanges, soft-tissue swelling, cardiac hypertrophy, hypertension,
diabetes, hirsutism, excessive skin tags, hypertrophic arthropathy, peripheral
neuropathy, hyperparathyroidism, hyperprolactinemia, and hypothyroidism.
While these stigmata often make the diagnosis obvious to the clinician,
their insidious onset often leads to significant delays in diagnosis.
Prolactin--Hypersecretion of prolactin may occur in 60% to 80%
of patients with pituitary tumors, although hyperprolactinemia may not
be the primary endocrinologic defect in many of these cases.[1,5] Elevation
of prolactin secondary to pituitary stalk compression may occur with any
mass within or extending out of the sella; however, a prolactin level above
200 ng/ml is usually accepted as evidence of a prolactin-secreting adenoma.
Elevated prolactin levels result in diminished levels of estrogen and testosterone.
Female patients generally develop menstrual irregularity or frank amenorrhea
or galactorrhea. Decreased libido occurs in both men and women.
Depression and mood alterations are associated with prolactin hypersecretion.
In general, men are less symptomatic from prolactin-secreting tumors, and
therefore, are more likely than women to have neurologic signs and symptoms
of disease and a macroadenoma.
Gonadotropins--Aberrant secretion of follicle-stimulating hormone
and luteinizing hormone is rare and is most often discovered after pituitary
adenomas produce neurologic symptoms. Occasionally, hypogonadism is a presenting
Thyrotropin--Thyroid-stimulating hormone excess occurs in less
than 1% of pituitary adenomas. The resultant hyperthyroidism is often presumed
to be of alternative etiology and is treated with thyroid-suppressing therapy.
Such treatment may be successful until neurologic symptoms occur. Therefore,
these tumors often grow to a large size and extend into adjacent structures,
making treatment difficult. Discovery of a microadenoma-secreting, thyroid-stimulating
hormone is rare, and this condition may be cured by addressing the pituitary
1. Leavens ME, McCutcheon IF, Samaan NA: Management of pituitary adenomas.
Oncology 6(6):69-79, 1992.
2. Hall WA, Luciano MG, Doppman JL, et al: Pituitary magnetic resonance
imaging in normal human volunteers: Occult adenomas in the general population.
Ann Intern Med 120(10):817-820, 1994.
3. Odell WD: Further considerations of therapy of pituitary tumors,
in Odell WD, Nelson DH, (eds): Pituitary Tumors, chap 11, pp 297-315. Mount
Kisko, New York, Future Publishing, 1984.
4. Comtois R, Beauregard H, Somma M, et al: The clinical and endocrine
outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas.
Cancer 68:860-866, 1991.
5. Smith MV, Laws ER, Jr.: Magnetic resonance imaging measurements of
pituitary stalk compression and deviation in patients with nonprolactin-secreting
intrasellar and paraseller tumors: Lack of correlation with serum prolactin
levels. Neurosurgery 34(5):834-839, 1994.
6. Ram Z, Shawker TH, Bradford MH, et al: Intraoperative ultrasound-directed
resection of pituitary tumors. J Neurosurg 83:225-230, 1995.
7. Gollard R, Kosty M, Cheney C, et al: Prolactin-secreting pituitary
carcinoma with implants in the cheek pouch and metastases to the ovaries:
A case report and literature review. Cancer 76:1814-1820, 1995.
8. Schoenthaler R, Albright NW, Wara WM, et al: Re-irradiation of pituitary
adenoma. Int J Radiat Oncol Biol Phys 24(2):307-314, 1992.
9. Davis DH, Laws ER, Jr., Ilstrup DM, et al: Results of surgical treatment
for growth hormone-secreting pituitary adenomas. J Neurosurg 79:70-75,
10. Arnott RD, Pestell RG, McKelvie PA, et al: A critical evaluation
of transsphenoidal pituitary surgery in the treatment of Cushing's disease:
Prediction of outcome. Acta Endocrinol 123:423-430, 1990.
11. Taylor SL, Tyrrell JB, Wilson CB: Delayed onset of hyponatremia
after transsphenoidal surgery for pituitary adenomas. Neurosurgery 37(4):649-654,
12. King WA, Rodts GE, Jr., Becker DP, et al: Microsurgical management
of giant pituitary tumors. Skull Base Surg 6(1):17-26, 1996.
13. Witt TC, Kondziolka D, Flickinger JC, et al: Stereotactic radiosurgery
for pituitary tumors, in Kondziolka D (ed): Radiosurgery 1995, pp 55-65.
Basel, Karger, 1996.
14. Parl FF, Cruz VE, Cobb CA, et al: Late recurrence of surgically
removed prolactinomas. Cancer 57:2422-2426, 1986.
15. Tsang RW, Brierley JD, Panzarella T, et al: Radiation therapy for
pituitary adenoma: Treatment outcome and prognostic factors. Int J Radiat
Oncol Biol Phys 30(3):557-565, 1994.
16. Grigsby PW, Simpson JR, Emami BN, et al: Prognostic factors and
results of surgery and postoperative irradiation in the management of pituitary
adenomas. Int J Radiat Oncol Biol Phys 16:1411-1417, 1989.
17. Zierhut D, Flentje M, Adolph J, et al: External radiotherapy of
pituitary adenomas. Int J Radiat Oncol Biol Phys 33:307-314, 1995.
18. Sohn JW, Dalzell JG, Suh JH, et al: Dose-volume histogram analysis
of techniques for irradiating pituitary adenomas. Int J Radiat Oncol Biol
Phys 32:831-837, 1995.
19. Tran LM, Blount L, Horton D, et al: Radiation therapy of pituitary
tumors: Results in 95 cases. Am J Clin Oncol 14(1):25-29, 1991.
20. Eastman RC, Gorden P, Roth J: Conventional supervoltage irradiation
is an effective treatment for acromegaly. J Clin Endocrinol Metab 48:931-940,
21. Fisher BJ, Gaspar LE, Noone B: Giant pituitary adenomas: Role of
radiotherapy. Int J Radiat Oncol Biol Phys 25(4):677-681, 1993.
22. Grattan-Smith PJ, Morris JGL, Shores EA, et al: Neuropsychological
abnormalities in patients with pituitary tumours. Acta Neurol Scand 86:626-631,
23. Armstrong C, Mollman J, Corn BW, et al: Effects of radiation therapy
on adult brain behavior: Evidence for a rebound phenomenon in a phase 1
trial. Neurology 43:1961-1965, 1993.
24. Wass JAH, Besser GM, Grossman A, et al: Second brain tumour after
treatment for pituitary adenoma. Br Med J 305:253-254, 1992.
25. Flickinger JC, Nelson PB, Taylor FH, et al: Incidence of cerebral
infarction after radiotherapy for pituitary adenoma. Cancer 63:2404-2408,
26. Bowen J, Paulsen CA: Stroke after pituitary irradiation. Stroke
27. Kjellberg RN, Kliman B: Lifetime effectiveness--A system of therapy
for pituitary adenomas, emphasizing Bragg peak proton hypophysectomy, in
Linfoot JA, (ed): Recent Advances in the Diagnosis and Treatment of Pituitary
Tumors, chap 19, pp 269-288. New York, Raven Press, 1979.
28. Degerblad M, Rahn T, Bergstrand G, et al: Long-term results of stereotactic
radiosurgery to the pituitary gland in Cushing's disease. Acta Endocrinol
29. Ganz JC, Backlund EO, Thorsen FA: The effects of gamma knife surgery
of pituitary adenomas on tumor growth and endocrinopathies. Stereotact
Funct Neurosurg 61(suppl 1):30-37, 1993.